Natixis Advisors LLC Purchases New Holdings in Insmed Incorporated (NASDAQ:INSM)

Natixis Advisors LLC bought a new stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 20,894 shares of the biopharmaceutical company's stock, valued at approximately $1,525,000.

Several other hedge funds have also modified their holdings of the stock. Kennedy Capital Management LLC purchased a new stake in shares of Insmed in the first quarter worth approximately $267,000. Russell Investments Group Ltd. grew its holdings in shares of Insmed by 15,915.2% during the 1st quarter. Russell Investments Group Ltd. now owns 22,101 shares of the biopharmaceutical company's stock valued at $600,000 after acquiring an additional 21,963 shares in the last quarter. TimesSquare Capital Management LLC purchased a new position in shares of Insmed during the 3rd quarter valued at $35,322,000. &PARTNERS acquired a new position in shares of Insmed in the second quarter worth $300,000. Finally, WCM Investment Management LLC raised its holdings in shares of Insmed by 58.6% during the third quarter. WCM Investment Management LLC now owns 148,330 shares of the biopharmaceutical company's stock worth $10,751,000 after acquiring an additional 54,806 shares in the last quarter.

Insider Activity

In other news, insider Martina M.D. Flammer sold 13,436 shares of the firm's stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the sale, the insider now owns 106,134 shares of the company's stock, valued at approximately $7,951,559.28. This trade represents a 11.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the transaction, the insider now directly owns 100,100 shares in the company, valued at $7,157,150. The trade was a 27.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 78,882 shares of company stock worth $5,765,446. Corporate insiders own 4.60% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on INSM shares. TD Cowen lifted their price target on Insmed from $75.00 to $98.00 and gave the company a "buy" rating in a report on Friday, August 9th. UBS Group increased their price target on shares of Insmed from $78.00 to $84.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. StockNews.com downgraded shares of Insmed from a "hold" rating to a "sell" rating in a report on Friday, August 9th. Bank of America upped their price objective on shares of Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Wednesday, October 9th. Finally, Stifel Nicolaus upped their price target on Insmed from $74.00 to $88.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, Insmed presently has a consensus rating of "Moderate Buy" and a consensus price target of $83.67.

Insmed Stock Performance

NASDAQ INSM traded up $1.41 during midday trading on Tuesday, hitting $75.50. The company had a trading volume of 531,799 shares, compared to its average volume of 2,233,366. The firm has a fifty day simple moving average of $72.05 and a two-hundred day simple moving average of $66.93. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The stock has a market cap of $13.51 billion, a price-to-earnings ratio of -13.35 and a beta of 1.12.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. The firm's quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.10) earnings per share. Equities analysts forecast that Insmed Incorporated will post -5.42 earnings per share for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.